Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725400 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TDP1MEN1KMT2AEPAS1 | |
| SCHEMBL2009048 | 0.82 | CYP2C9 (0.36) | ALDH1A1TDP1MEN1KMT2AEPAS1 | |
| SCHEMBL30826192 | 0.78 | ERN1 (0.36) | ALDH1A1TDP1MEN1KMT2ACYP2C9 | |
| SCHEMBL29447959 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TDP1MEN1KMT2AHSD17B10 | |
| SCHEMBL953875 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TDP1MEN1KMT2AEPAS1 | |
| SCHEMBL23647903 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TDP1MEN1KMT2AHSD17B10 | |
| SCHEMBL615646 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TDP1MEN1KMT2AHSD17B10 | |
| SCHEMBL20872683 | 0.76 | GABRA1 (0.43) | ALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL21884804 | 0.75 | ERN1 (0.44) | ALDH1A1TDP1MEN1KMT2ACYP3A4 | |
| SCHEMBL22445291 | 0.75 | ERN1 (0.41) | CYP2C9CYP3A4CYP2C19ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642778-A1 | LSD1 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20240327425-A1 | KRAS G12D INHIBITOR AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |
| EP-4393919-A1 | LSD1 MODULATORS | Exscientia Al Limited (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-4365176-A1 | KRAS G12D INHIBITOR AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023274383-A1 | KRAS G12D INHIBITOR AND USE THEREOF | 上海迪诺医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| CN-115557974-A | KRAS G12D inhibitor and application thereof | 上海迪诺医药科技有限公司 | 2023-01-03 | — | — | CN | disclosed |
| EP-4083032-A1 | PD-L1 ANTAGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021129584-A1 | PD-L1 ANTAGONIST COMPOUND | 杭州阿诺生物医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| CN-101679288-A | Indazoles for treating estrogen receptor beta mediated diseases | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2118068-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008107455-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107455-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327425-A1 | KRAS G12D INHIBITOR AND USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 2457/4885TDP1 4080/4885MEN1 204/4885 |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GPER1, ESR2, ESRRB | ALDH1A1 746/4885TDP1 3952/4885MEN1 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.